» Articles » PMID: 38467885

Group 3 Innate Lymphoid Cells in Intestinal Health and Disease

Overview
Specialty Gastroenterology
Date 2024 Mar 12
PMID 38467885
Authors
Affiliations
Soon will be listed here.
Abstract

The gastrointestinal tract is an immunologically rich organ, containing complex cell networks and dense lymphoid structures that safeguard this large absorptive barrier from pathogens, contribute to tissue physiology and support mucosal healing. Simultaneously, the immune system must remain tolerant to innocuous dietary antigens and trillions of normally beneficial microorganisms colonizing the intestine. Indeed, a dysfunctional immune response in the intestine underlies the pathogenesis of numerous local and systemic diseases, including inflammatory bowel disease, food allergy, chronic enteric infections or cancers. Here, we discuss group 3 innate lymphoid cells (ILC3s), which have emerged as orchestrators of tissue physiology, immunity, inflammation, tolerance and malignancy in the gastrointestinal tract. ILC3s are abundant in the developing and healthy intestine but their numbers or function are altered during chronic disease and cancer. The latest studies provide new insights into the mechanisms by which ILC3s fundamentally shape intestinal homeostasis or disease pathophysiology, and often this functional dichotomy depends on context and complex interactions with other cell types or microorganisms. Finally, we consider how this knowledge could be harnessed to improve current treatments or provoke new opportunities for therapeutic intervention to promote gut health.

Citing Articles

T-betILC3 in peripheral blood is increased in the ankylosing spondylitis with high disease activity.

Liu Y, Shen Y, Ding H, He D, Cheng P, Wu X Heliyon. 2025; 11(1):e41678.

PMID: 39866450 PMC: 11757778. DOI: 10.1016/j.heliyon.2025.e41678.


Group 3 Innate Lymphoid Cells: A Potential Therapeutic Target for Steroid Resistant Asthma.

Berkinbayeva M, Gu W, Chen Z, Gao P Clin Rev Allergy Immunol. 2025; 68(1):1.

PMID: 39751959 PMC: 11698894. DOI: 10.1007/s12016-024-09012-3.


Host-pathobiont interactions in Crohn's disease.

Caruso R, Lo B, Chen G, Nunez G Nat Rev Gastroenterol Hepatol. 2024; .

PMID: 39448837 DOI: 10.1038/s41575-024-00997-y.


RIPK3 and caspase-8 interpret cytokine signals to regulate ILC3 survival in the gut.

Joseph A, Ahmed A, Goc J, Horn V, Fiedler B, Garone D Mucosal Immunol. 2024; 17(6):1212-1221.

PMID: 39137882 PMC: 11637958. DOI: 10.1016/j.mucimm.2024.08.004.


A little ER stress isn't bad: the IRE1α/XBP1 pathway shapes ILC3 functions during intestinal inflammation.

Fionda C, Sciume G J Clin Invest. 2024; 134(13).

PMID: 38949019 PMC: 11213460. DOI: 10.1172/JCI182204.


References
1.
Sawa S, Cherrier M, Lochner M, Satoh-Takayama N, Fehling H, Langa F . Lineage relationship analysis of RORgammat+ innate lymphoid cells. Science. 2010; 330(6004):665-9. DOI: 10.1126/science.1194597. View

2.
Villablanca E, Selin K, Hedin C . Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?. Nat Rev Gastroenterol Hepatol. 2022; 19(8):493-507. DOI: 10.1038/s41575-022-00604-y. View

3.
Guendel F, Kofoed-Branzk M, Gronke K, Tizian C, Witkowski M, Cheng H . Group 3 Innate Lymphoid Cells Program a Distinct Subset of IL-22BP-Producing Dendritic Cells Demarcating Solitary Intestinal Lymphoid Tissues. Immunity. 2020; 53(5):1015-1032.e8. DOI: 10.1016/j.immuni.2020.10.012. View

4.
Forkel M, Mjosberg J . Dysregulation of Group 3 Innate Lymphoid Cells in the Pathogenesis of Inflammatory Bowel Disease. Curr Allergy Asthma Rep. 2016; 16(10):73. PMC: 5028403. DOI: 10.1007/s11882-016-0652-3. View

5.
Klose C, Flach M, Mohle L, Rogell L, Hoyler T, Ebert K . Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell. 2014; 157(2):340-356. DOI: 10.1016/j.cell.2014.03.030. View